Skip Nav Destination
Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia
Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy
MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia
Issue Archive
January 14 2020
Table of Contents
BLOOD ADVANCES TALK
TESTING ADVANCES
Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia
Clinical Trials & Observations
EXCEPTIONAL CASE REPORT
Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement
Clinical Trials & Observations
Valentina Nardi,Nora Ku,Matthew J. Frigault,Adrian M. Dubuc,Harrison Kwei Tsai,Philip C. Amrein,Gabriela S. Hobbs,Andrew M. Brunner,Rupa Narayan,Meghan E. Burke,Julia Foster,Paola Dal Cin,Marcela V. Maus,Amir T. Fathi,Hanno Hock
STIMULUS REPORTS
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma
Clinical Trials & Observations
Tim M. Illidge,Elizabeth H. Phillips,Nicholas Counsell,Ruth Pettengell,Peter W. M. Johnson,Dominic J. Culligan,Bilyana Popova,Laura Clifton-Hadley,Andrew McMillan,Peter Hoskin,Sally F. Barrington,John Radford
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
Clinical Trials & Observations
Armando Santoro,Rita Mazza,Alessandro Pulsoni,Alessandro Re,Maurizio Bonfichi,Vittorio Ruggero Zilioli,Manuela Zanni,Francesco Merli,Antonella Anastasia,Stefano Luminari,Giorgia Annechini,Manuel Gotti,Annalisa Peli,Anna Marina Liberati,Nicola Di Renzo,Luca Castagna,Laura Giordano,Francesca Ricci,Carmelo Carlo-Stella
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Clinical Trials & Observations
Zhaohui Du,Niels Weinhold,Gregory Chi Song,Kristin A. Rand,David J. Van Den Berg,Amie E. Hwang,Xin Sheng,Victor Hom,Sikander Ailawadhi,Ajay K. Nooka,Seema Singhal,Karen Pawlish,Edward S. Peters,Cathryn Bock,Ann Mohrbacher,Alexander Stram,Sonja I. Berndt,William J. Blot,Graham Casey,Victoria L. Stevens,Rick Kittles,Phyllis J. Goodman,W. Ryan Diver,Anselm Hennis,Barbara Nemesure,Eric A. Klein,Benjamin A. Rybicki,Janet L. Stanford,John S. Witte,Lisa Signorello,Esther M. John,Leslie Bernstein,Antoinette M. Stroup,Owen W. Stephens,Maurizio Zangari,Frits Van Rhee,Andrew Olshan,Wei Zheng,Jennifer J. Hu,Regina Ziegler,Sarah J. Nyante,Sue Ann Ingles,Michael F. Press,John David Carpten,Stephen J. Chanock,Jayesh Mehta,Graham A. Colditz,Jeffrey Wolf,Thomas G. Martin,Michael Tomasson,Mark A. Fiala,Howard Terebelo,Nalini Janakiraman,Laurence Kolonel,Kenneth C. Anderson,Loic Le Marchand,Daniel Auclair,Brian C.-H. Chiu,Elad Ziv,Daniel Stram,Ravi Vij,Leon Bernal-Mizrachi,Gareth J. Morgan,Jeffrey A. Zonder,Carol Ann Huff,Sagar Lonial,Robert Z. Orlowski,David V. Conti,Christopher A. Haiman,Wendy Cozen
GENE THERAPY
HEALTH SERVICES AND OUTCOMES
LYMPHOID NEOPLASIA
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT
Clinical Trials & Observations
Talha Badar,Narendranath Epperla,Aniko Szabo,Steven Borson,John Vaughn,Gemlyn George,Neeraj Saini,Abdul Rashid Shah,Romil D. Patel,Sairah Ahmed,Nirav N. Shah,Amanda F. Cashen,Mehdi Hamadani,Timothy S. Fenske
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault,Philippe Armand,Robert A. Redd,Erin Jeter,Reid W. Merryman,Kimberly C. Coleman,Alex F. Herrera,Parastoo Dahi,Yago Nieto,Ann S. LaCasce,David C. Fisher,Samuel Y. Ng,Oreife O. Odejide,Arnold S. Freedman,Austin I. Kim,Jennifer L. Crombie,Caron A. Jacobson,Eric D. Jacobsen,Jeffrey L. Wong,Jad Bsat,Sanjay S. Patel,Jerome Ritz,Scott J. Rodig,Margaret A. Shipp,Yi-Bin Chen,Robin M. Joyce
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
Xia Liu,Jiaji G. Chen,Manit Munshi,Zachary R. Hunter,Lian Xu,Amanda Kofides,Nickolas Tsakmaklis,Maria G. Demos,Maria Luisa Guerrera,Gloria G. Chan,Cristina Jimenez,Christopher J. Patterson,Kirsten Meid,Andrew Keezer,Jorge J. Castillo,Steven P. Treon,Guang Yang
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
Clinical Trials & Observations
Thomas E. Lew,Mary Ann Anderson,Victor S. Lin,Sasanka M. Handunnetti,Neil A. Came,Piers Blombery,David A. Westerman,Meaghan Wall,Constantine S. Tam,Andrew W. Roberts,John F. Seymour
MYELOID NEOPLASIA
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Clinical Trials & Observations
Yuichi Ishikawa,for the Japan Adult Leukemia Study Group,Naomi Kawashima,for the Japan Adult Leukemia Study Group,Yoshiko Atsuta,for the Japan Adult Leukemia Study Group,Isamu Sugiura,for the Japan Adult Leukemia Study Group,Masashi Sawa,for the Japan Adult Leukemia Study Group,Nobuaki Dobashi,for the Japan Adult Leukemia Study Group,Hisayuki Yokoyama,for the Japan Adult Leukemia Study Group,Noriko Doki,for the Japan Adult Leukemia Study Group,Akihiro Tomita,for the Japan Adult Leukemia Study Group,Toru Kiguchi,for the Japan Adult Leukemia Study Group,Shiro Koh,for the Japan Adult Leukemia Study Group,Heiwa Kanamori,for the Japan Adult Leukemia Study Group,Noriyoshi Iriyama,for the Japan Adult Leukemia Study Group,Akio Kohno,for the Japan Adult Leukemia Study Group,Yukiyoshi Moriuchi,for the Japan Adult Leukemia Study Group,Noboru Asada,for the Japan Adult Leukemia Study Group,Daiki Hirano,for the Japan Adult Leukemia Study Group,Kazuto Togitani,for the Japan Adult Leukemia Study Group,Toru Sakura,for the Japan Adult Leukemia Study Group,Maki Hagihara,for the Japan Adult Leukemia Study Group,Tatsuki Tomikawa,for the Japan Adult Leukemia Study Group,Yasuhisa Yokoyama,for the Japan Adult Leukemia Study Group,Norio Asou,for the Japan Adult Leukemia Study Group,Shigeki Ohtake,for the Japan Adult Leukemia Study Group,Itaru Matsumura,for the Japan Adult Leukemia Study Group,Yasushi Miyazaki,for the Japan Adult Leukemia Study Group,Tomoki Naoe,for the Japan Adult Leukemia Study Group,Hitoshi Kiyoi,for the Japan Adult Leukemia Study Group
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells
Karen Phaik Har Lim,Paul Milne,Michael Poidinger,Kaibo Duan,Howard Lin,Naomi McGovern,Harshal Abhyankar,Daniel Zinn,Thomas M. Burke,Olive S. Eckstein,Rikhia Chakraborty,Amel Sengal,Brooks Scull,Evan Newell,Miriam Merad,Kenneth L. McClain,Tsz-Kwong Man,Florent Ginhoux,Matthew Collin,Carl E. Allen
PLATELETS AND THROMBOPOIESIS
THROMBOSIS AND HEMOSTASIS
GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets
Xi Chen,Shuchi Gupta,Matthew Cooper,Daniel DeHelian,Xuefei Zhao,Meghna U. Naik,Jeremy G. T. Wurtzel,Timothy J. Stalker,Lawrence E. Goldfinger,Jeffrey Benovic,Lawrence F. Brass,Steven E. McKenzie,Ulhas P. Naik,Peisong Ma
Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy
Clinical Trials & Observations
Joan Cox Gill,Stephen F. Conley,Victoria P. Johnson,Pamela A. Christopherson,Sandra L. Haberichter,Christina D. Diaz,Tatyana C. Strong,Jian Zhang,Pippa Simpson,Thomas C. Abshire,Robert R. Montgomery,Veronica H. Flood
MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia
Clinical Trials & Observations
Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor
Steven P. Grover,Clare M. Schmedes,Alyson C. Auriemma,Emily Butler,Molly L. Parrish,Adam Miszta,Audrey C. Cleuren,Mayken Visser,Stefan Heitmeier,Jens J. Posma,Henri M. Spronk,Silvio Antoniak,Alisa S. Wolberg,Rafal Pawlinski,David Gailani,Nigel Mackman
TRANSPLANTATION
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia
Clinical Trials & Observations
Yoshihiro Inamoto,Stephanie J. Lee,Lynn E. Onstad,Mary E. D. Flowers,Betty K. Hamilton,Madan H. Jagasia,Paul J. Martin,Steven Z. Pavletic,Joseph A. Pidala,Iskra Pusic,Georgia B. Vogelsang,Daniel Wolff,Paul A. Carpenter
ERRATUM
-
Cover Image
Cover Image
COVER FIGURE
Circos plot illustrating the association of mutated genes in acute myeloid leukemia (AML) with RUNX1-RUNX1T1 or CBFB-MYH11. KIT mutation is the most frequently identified in AML with RUNX1-RUNX1T1, while NRAS mutation is the most frequent in AML with CBFB-MYH11. See the article by Ishikawa et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals